News

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

GLOBENEWSWIRE | Entasis Therapeutics, a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that top-line data from the company’s pivotal Phase 3 ATTACK trial was presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference.

Full Story